Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2008 June;60(2) > Minerva Urologica e Nefrologica 2008 June;60(2):93-103

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  UPDATE ON URODYNAMICS


Minerva Urologica e Nefrologica 2008 June;60(2):93-103

language: English

The use of botulinum toxin for treatment of lower urinary tract symptoms

Lucioni A. 1, Reynolds W. S. 1, Rapp D. E. 2, Katz M. 1, Bales G. T. 1

1 Section of Urology, Department of Surgery University of Chicago Medical Center, Chicago, IL, USA
2 Section of Urology, Department of Surgery Virginia Mason Medical Center, Seattle, WA, USA


PDF  REPRINTS


In the last decade we have seen the emergence of botulinum toxin (BTX) as a successful treatment of patients with neurogenic and idiopathic detrusor overactivity that are refractory to antimuscarinic medication. The success of BTX in this patient population has led to use BTX in patients with other causes of lower urinary tract symptoms such as benign prostatic hyperplasia (BPH) and urethral sphincter anomalies. Despite this success, the protocol for BTX injection has not yet been standardized. Various studies are on the way in order to determine the best injection protocol for bladder injection of BTX. The use of BTX in patients with BPH is in its early stages. Further large randomized controls trials in patients with BPH are needed to determine the efficacy of BTX in this patient population.

top of page